GT Biopharma to Showcase Cutting-Edge NK Cell Engager Therapeutics
GT Biopharma, Inc. (NASDAQ: GTBP), an innovative company in the clinical-stage immuno-oncology space, is thrilled to announce an upcoming virtual Key Opinion Leader (KOL) event. This event will focus on their exciting array of therapies based on natural killer (NK) cell engager technology. Attendees can expect valuable insights into the NK cell therapy landscape, along with a chance to interact with leading experts in this field.
Details of the Virtual KOL Event
Mark your calendars for October 10, 2024, at 12:00 PM ET for this virtual event. The session will feature esteemed researchers like Dr. Jeffrey Miller and Dr. Mark Juckett from the University of Minnesota Medical School. They will talk about the vast potential of NK cell therapies, addressing both the challenges currently faced in the field and the promising future directions for these treatments, which are expanding beyond cancer to include inflammatory autoimmune diseases.
Insights from Leading Experts
Dr. Miller, who has a wealth of experience in NK cell research, will give a detailed overview of GT Biopharma's proprietary TriKE® platform. He'll explain how these engagers fit into the broader therapeutic landscape. In addition to that, he will cover the promising Phase 1 clinical trial set to evaluate GTB-3650 monotherapy specifically for acute myeloid leukemia (AML). This highlights the company's commitment to advancing innovative therapies to fight challenging blood cancers.
Interactive Q&A Session
The session will wrap up with an interactive question-and-answer segment, giving participants the chance to ask the experts about ongoing clinical developments in NK cell therapy and to gain more in-depth insights.
About the Speakers
Dr. Jeffrey Miller serves as the Consulting Senior Medical Director at GT Biopharma. With a strong background in NK cell biology, his lab specializes in enhancing the functionality of NK cells for cancer treatment. Dr. Miller has made significant contributions by providing numerous NK cell products to patients and investigating the possibility of using induced pluripotent stem cell (iPSC) derived NK cells as an off-the-shelf treatment option.
Dr. Mark Juckett is an integral part of the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. He is dedicated to treating blood cancer patients and emphasizes a patient-centered approach, integrating the latest research into clinical practice to enhance outcomes for those battling complex conditions like acute leukemia.
Innovative Approaches in Immuno-Oncology
GT Biopharma is dedicated to leading the way in immuno-oncology advancements. Its TriKE® platform seeks to leverage the innate abilities of natural killer cells to more effectively fight cancer. By developing groundbreaking biotherapeutics, GT Biopharma aims to transform the management of patients facing difficult-to-treat cancers. Their collaboration with the University of Minnesota highlights their commitment to exploring new therapeutic avenues while addressing critical needs in oncology care.
Conclusion
As the field of immuno-oncology continues to advance, GT Biopharma is positioning itself at the forefront of innovation. With ongoing studies and a dedicated team of experts, the company's work to enhance NK cell therapy could lead to groundbreaking treatments that not only fill existing therapeutic gaps but also bring new hope to patients facing serious blood disorders.
Frequently Asked Questions
What is the purpose of the virtual KOL event?
The virtual KOL event aims to showcase GT Biopharma's NK cell engager pipeline and their advancements in immuno-oncology therapies, along with insights from leading experts.
Who are the featured speakers at the event?
The event will feature Dr. Jeffrey Miller and Dr. Mark Juckett from the University of Minnesota Medical School, both known for their expertise in NK cell therapies and blood cancers.
What is GTB-3650?
GTB-3650 is a monotherapy currently being studied in a Phase 1 clinical trial for treating acute myeloid leukemia (AML), reflecting one of GT Biopharma's innovative therapeutic strategies.
What is the TriKE® platform?
The TriKE® platform developed by GT Biopharma enhances the cancer-fighting capabilities of NK cells using innovative engager technology, with the goal of improving patient outcomes.
How can I participate in the event?
To participate in the event, registration details will be shared as the date approaches, enabling interested individuals to reserve their spot.
